• The gold market’s current dynamics underscore the metal’s enduring appeal
• Lahontan Gold boasts a portfolio of four gold and silver projects located in Nevada’s prolific Walker Lane
• LGCXF’s management team comprises seasoned professionals with extensive experience in mineral exploration, project development and corporate finance
• LGCXF recently named as “one of the best gold developers in Nevada”

In an era marked by economic volatility and geopolitical tensions, gold has reasserted itself as a premier safe-haven asset. Gold prices have soared to unprecedented levels, surpassing $3,400 per ounce, driven by factors such as trade disputes, inflationary pressures and global uncertainty (https://ibn.fm/1Z7sV). This bullish trend has reignited interest in gold mining ventures, with companies such as Lahontan Gold (TSX.V: LG) (OTCQB: LGCXF) emerging as compelling opportunities for investors seeking exposure to the precious metals sector.

The gold market’s current dynamics underscore the metal’s enduring appeal. In 2025 alone, gold has experienced a remarkable 25% year-to-date increase, reflecting a convergence of market forces, including aggressive central bank accumulation and evolving monetary policies. This surge has not only elevated gold’s status among institutional investors but has also spotlighted the potential of mining companies poised to capitalize on the heightened demand (https://ibn.fm/W2vPX).

Investors are increasingly turning to gold mining stocks as a strategic avenue to benefit from rising gold prices (https://ibn.fm/oLUmF). The sector has witnessed a notable uptick in activity, and this trend is further bolstered by the sector’s historically low valuations and its low correlation with traditional equities, offering diversification benefits to investment portfolios. In a recent post, mining analyst Don Durrett described Lahontan Gold Corp as “one of the best gold developers in Nevada,” calling it “cheap and a sleeper” with “10 bagger” potential if gold prices surpass $2500 and the company hits its feasibility study timeline by 2026.

Amid this favorable backdrop, Lahontan Gold Corp. has positioned itself as a noteworthy player in the gold exploration and development landscape. The company boasts a portfolio of four gold and silver projects located in Nevada’s prolific Walker Lane, a region renowned for its rich mineral endowment and mining-friendly jurisdiction. Lahontan’s flagship asset, the Santa Fe Mine, is a past-producing open-pit operation that yielded 345,000 ounces of gold and 710,000 ounces of silver, underscoring its significant resource potential (https://ibn.fm/QTBnL).

Recent developments have further enhanced the Santa Fe project’s appeal. A Preliminary Economic Assessment (“PEA”) released earlier this year highlighted the project’s robust economics, with an updated mineral resource estimate indicating nearly 2 million ounces of gold equivalent (https://ibn.fm/OhmXb). Notably, metallurgical testing revealed cyanide-soluble gold recoveries of up to 91.5%, suggesting favorable processing characteristics and potential for cost-effective extraction.

Lahontan’s strategic focus extends beyond Santa Fe. The company’s additional projects—Moho, West Santa Fe, and Redlich—are all situated within Nevada, providing logistical advantages and operational synergies. These properties are at various stages of exploration, with ongoing drilling and assessment activities aimed at delineating resources and advancing them toward development.

Leadership plays a pivotal role in Lahontan’s trajectory. The management team comprises seasoned professionals with extensive experience in mineral exploration, project development and corporate finance. Their collective expertise is instrumental in navigating the complexities of the mining industry and executing the company’s growth strategy.

As gold continues to shine amid global economic uncertainties, companies such as Lahontan Gold offer investors a unique opportunity to participate in the sector’s upside potential. With a robust project portfolio, promising resource base and experienced leadership, Lahontan is well-positioned to capitalize on the prevailing market conditions and contribute to the resurgence of gold mining in the United States.

For more information, visit the company’s website at www.LahontanGoldCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to LGCXF are available in the company’s newsroom at https://ibn.fm/LGCXF

• The company’s non-invasive fingerprint drug screening system uses fingerprint sweat to screen for drugs such as cannabis, cocaine, methamphetamine, and opiates.
• Results are available in under ten minutes, supporting faster, on-site decision-making in treatment and justice settings.
• INBS is pursuing FDA approval and further entry into the U.S. market, where it currently operates in a Forensic Use Only capacity.
• The company has over 450 active accounts in 24 countries, targeting sectors such as healthcare, justice, and workplace safety.
• INBS partnered with SMARTOX, a U.S. distributor, to connect with stakeholders in criminal justice and addiction recovery.

Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company specializing in rapid, non-invasive testing solutions, recently attended the RISE25 conference to demonstrate its portable Intelligent Fingerprint Drug Screening System, continuing its push into the U.S. market for rapid, non-invasive screening technologies (https://ibn.fm/1JSTS).

The event, held May 28–31 in Florida, attracted over 7,000 professionals from the fields of addiction treatment, mental health, and criminal justice. The conference has become a national gathering point for those working on evidence-based approaches to substance use and behavioral health issues.

At the conference, INBS presented its system alongside its U.S. distribution partner SMARTOX. SMARTOX, founded in 2012, provides drug and alcohol testing services across a wide range of institutional settings in the United States. The firm offers a full-service model, including distribution, customer support, and program design.

INBS’s drug screening system, designed for forensic use in the United States, detects recent drug use by analyzing fingerprint sweat. It screens for cannabis, cocaine, methamphetamine, and opiates, producing results in under ten minutes.

INBS President and CEO Harry Simeonidis and Vice President of Global Sales Doug Heath were present at the event, joining SMARTOX’s Vice President of Sales and Marketing, Duffy Nabors, in demonstrating the system’s potential applications.

The system’s portability and ease of use are well-suited to environments where rapid screening and privacy are important, such as treatment courts, probation programs, and correctional settings. The fingerprint sweat-based system offers an alternative to traditional urine or saliva tests, with less need for invasive procedures or secure facilities.

Heath emphasized the importance of delivering “effective screening methods for justice-involved individuals,” particularly in programs focused on recovery and rehabilitation rather than incarceration. “The RISE conference represents a national effort to transform justice responses to substance use and mental health,” said Heath. “We’re proud to support SMARTOX in showcasing our solution and to contribute to the conversation around dignity, access, and effective screening methods for justice-involved individuals.”

The company’s attendance at RISE25 reflects its broader strategy to position the technology in the U.S. justice and public health sectors. Currently, the system is approved only for forensic use in the U.S., but INBS is seeking broader FDA clearance.

Outside the U.S., the company’s drug testing system is already deployed in sectors such as construction, manufacturing, transport, and drug treatment. In total, INBS reports more than 450 active accounts across 24 countries, reflecting growing global interest in rapid, on-site testing tools.

For INBS, the U.S. forensic market offers a testbed for its system, while regulatory progress may open up opportunities in other high-demand areas such as workplace safety and healthcare. The company’s participation in RISE25 provided a direct channel to policymakers, researchers, and court officials interested in more efficient screening methods.

For more information, visit the company’s website at https://ibs.inc.

NOTE TO INVESTORS: The latest news and updates relating to INBS are available in the company’s newsroom at http://ibn.fm/INBS

• ESGold is a gold and silver company preparing for production later this year at a tailings reclamation site in Quebec abandoned by the previous operator
• The gold and silver resource developer expects to concentrate on reprocessing the tailings for the near-term to extract mica and any remaining gold and silver, anticipating that the resulting mica concentrate will be useful in a wide variety of building and roadwork materials
• ESGold plans to build revenue through the reuse project, which can then help fund planned exploration at its Quebec property covering 13,116 hectares (about 32,410 acres)
• The company is currently conducting testing to see if it can effectively streamline production by processing gold and silver in one of the tailings sites at the property into a concentrate that would allow the company to bypass traditional circuit steps and pour bullion directly on site

Gold and silver company ESGold (CSE: ESAU) (OTCQB: ESAUF) is testing a potential refining process that may reduce the company’s costs and environmental impact as it ramps up preparations for starting a tailings production operation.

ESGold holds 265 mining claims on the historic Montauban mine site in Quebec, covering 13,116 hectares (about 32,410 acres) 80 kilometers (49.7 miles) west of the province’s capital city.

The company is readying a rehabilitation project that will reprocess tailings abandoned by a former operator starting this fall, which will in turn help to fund anticipated new gold and silver exploration at the property.

The refining process being tested uses a Humphrey spiral concentrator similar to others installed in a plant on the site for the fall operation, which will use the concentrators in a gravity separation circuit designed to process up to 1,000 metric tons per day (“TPD”) of the site’s tailings (https://ibn.fm/JRTYC).

But the testing under way at the site is assessing the potential for generating a high-grade concentrate of gold and silver, drawing feedstock material from a historic stockpile known to contain significantly higher concentrations of gold and silver than the Anacon Lead 1 tailings site identified by the company as its primary focus for reclamation.

ESGold’s goal is to produce a concentrate representing less than 3 percent of the feed mass while capturing more than 50 percent of the gold and silver content, which could allow the company to bypass traditional circuit steps and pour bullion directly on site, according to a news release published May 30 (https://ibn.fm/1L1Hc).

Success in achieving the goal would permit the company to reduce processing time, optimizing throughput efficiency, and reduce cyanide consumption in the process to sustain ESGold’s low-environmental-footprint aims.

The testing is expected to take a week, with lab results expected within a month of completing the test.

ESGold is working with private consultancy DMCMS Inc. to deliver environmentally friendly, sustainable materials using a clean technology that fuses mine waste with an organic polymer to create a concentrate stronger than concrete that will be useful in building materials such as bricks, cinder blocks, paving stones, patio tiles, parking columns, and highway Jersey barriers.

“Most companies do a ton of exploration, then have to get their permits and have to go into production. We’re not. We’re going to be cash-flow positive by this time (in 2025),” ESGold President and Director Brad Kitchen said in a November 2024 interview (https://ibn.fm/4tvX2).

For more information, visit the company’s website at https://esgold.com.

NOTE TO INVESTORS: The latest news and updates relating to ESAUF are available in the company’s newsroom at https://ibn.fm/ESAUF

• Soligenix’s HyBryte(TM) is a photodynamic therapy using synthetically manufactured hypericin, one of the most photoactive compounds available.
• The therapeutic potential of HyBryte(TM) has been demonstrated through multiple clinical trials, including a Phase 3 trial in early-stage CTCL patients.
• HyBryte(TM) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration and the European Medicines Agency.

Cutaneous T-cell lymphoma (“CTCL”) is a rare and debilitating form of non-Hodgkin’s lymphoma that primarily affects the skin, posing both physical and emotional challenges for those diagnosed. With limited treatment options available and no definitive cure, the need for innovative, safe and effective therapies is urgent. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is focused on developing and commercializing products to treat rare diseases. At the forefront of Soligenix’s pipeline is HyBryte(TM), a novel therapy aimed at treating early-stage CTCL.

CTCL affects the skin by causing malignant T-cells to accumulate in the upper layers, often resulting in patches, plaques and tumors that can be intensely itchy, painful, and disfiguring. The disease can significantly impair quality of life and, in more advanced stages, may involve other parts of the body such as the lymph nodes, blood and internal organs.

According to the Cutaneous Lymphoma Foundation, approximately 3,000 new cases of CTCL are diagnosed in the United States each year, with an estimated 30,000 to 40,000 individuals living with the disease nationwide (https://ibn.fm/Rh6HC). While CTCL tends to progress slowly, it is chronic and currently incurable, requiring ongoing treatment to manage symptoms and improve patients’ quality of life.

This chronic nature makes the search for better treatment solutions even more critical, especially as existing therapies often involve systemic immunosuppressants, phototherapy or chemotherapy, which can carry serious side effects and limit long-term effectiveness. The need for treatments that are not only effective but also safe and tolerable over long durations is pressing.

Soligenix’s HyBryte(TM) (synthetic hypericin) is a photodynamic therapy using synthetically manufactured hypericin, which is one of the most photoactive compounds available (https://ibn.fm/6L6oR). Used in ointment or gel form, synthetic hypericin is combined with visible fluorescent or LED light. Because it is easily activated with relatively low-energy light, HyBryte(TM) is ideal for photodynamic therapy because it can be activated with safe visible light instead of damaging UVA or UVB light, which are associated with increased cancer risks.

This mechanism is particularly significant in treating CTCL, a condition that often requires repeated and prolonged skin treatments. HyBryte(TM) offers a noninvasive alternative that may reduce the cumulative toxicity and side effects often seen with current options.

The therapeutic potential of HyBryte(TM) has been demonstrated in multiple clinical trials, including a Phase 3 trial in early-stage CTCL patients. The company recently released interim results from the ongoing open-label, investigator-initiated study (“IIS”) evaluating extended HyBryte(TM) treatment for up to 54 weeks in patients with early-stage CTCL (https://ibn.fm/N3np8). Following 18 weeks of treatment, 75% of patients achieved “treatment success,” reinforcing HyBryte(TM) as a potentially safe and fast-acting therapy for this chronic and underserved cancer.

In January 2025, Soligenix announced expanded access treatment results that also showed positive outcomes, reinforcing the drug’s safety and efficacy profile in real-world applications (https://ibn.fm/ntbfY). Patients who continued treatment beyond the original trial timeline maintained or improved their clinical responses, a particularly encouraging outcome in the management of a disease known for its relapsing and remitting course.

HyBryte(TM) has also been granted Orphan Drug Designation by the U.S. Food and Drug Administration (“FDA”), which provides regulatory incentives including market exclusivity, tax credits for clinical testing, and exemption from user fees. This designation not only underscores the drug’s potential to address an unmet medical need but also enhances its commercial viability, if approved. Furthermore, Soligenix has expressed intentions to pursue marketing approval worldwide, including the European Union, where HyBryte(TM) has also received Orphan Drug Designation from the European Medicines Agency (“EMA”), which could pave the way for broader access to the treatment and significant benefits for patients globally.

In addition, Soligenix is engaging with the broader medical and scientific communities to ensure HyBryte’s(TM) integration into treatment protocols, should regulatory approval be granted. As the company continues to build on its clinical successes, its commitment to innovation in rare disease treatment remains clear. The development of HyBryte(TM) for CTCL reflects Soligenix’s broader mission: to deliver novel treatment solutions for underserved patient populations. With the increasing prevalence of CTCL and the limited scope of current treatment options, HyBryte(TM) could represent a much-needed breakthrough in how the disease is managed, offering new hope to thousands of individuals living with this complex and chronic lymphoma.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

• The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a planned national clinic network, and is expected to immediately improve revenue and EBITDA for NRx and HOPE Therapeutics.
• HOPE aims to develop a network of up to 30 interventional psychiatry clinics by the end of 2025, with a $100 million pro forma run rate by YE 25.
• Kadima specializes in interventional psychiatry, and Kadima’s founder Dr. David Feifel, will join HOPE as Chief Medical Innovation Officer.
• NRx’s broader pipeline includes FDA-designated treatments for bipolar depression and acute suicidality.

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, known for treating suicidal bipolar depression and acute suicidal depression, has signed a definitive agreement to acquire Kadima Neuropsychiatry Institute. The Kadima acquisition agreement (not yet closed) is part of HOPE’s strategy to establish a scalable mental health treatment network of interventional psychiatry clinics. (https://ibn.fm/DjOMz).

Kadima, located in La Jolla, California, will become the clinical and operational template for the proposed network. Known for its work in interventional psychiatry, the clinic’s integration with HOPE Therapeutics is expected to drive immediate financial gains, including EBITDA growth.

HOPE Therapeutics is targeting the acquisition of up to 30 clinics by the end of 2025, with a $100 million pro forma run rate by YE 25. The company is positioning these clinics to address critical gaps in care for patients experiencing suicidal depression, post-traumatic stress disorder, and other complex mental health conditions.

Dr. David Feifel, founder of Kadima and a recognized figure in interventional psychiatry, will take on the role of Chief Medical Innovation Officer at HOPE Therapeutics. His appointment is viewed as a key asset for the company’s clinical strategy. “Dr. David Feifel is a true pioneer in interventional psychiatry and we are honored to have him join our leadership team,” said HOPE Co-CEOs Dr. Jonathan Javitt and Matthew Duffy. “With his guidance, we are accelerating the buildout of a world-class clinic network that integrates cutting-edge science with community-based care.”

The acquisition of Kadima is part of a broader expansion by HOPE Therapeutics into the outpatient psychiatric treatment space. Additional agreements are already in place to acquire Dura Medical and a letter of intent has been signed with Neurospa TMS. This expansion reflects growing demand for more accessible, evidence-based interventions in psychiatric care, including ketamine-based treatments and neuromodulation techniques.

Kadima’s offerings include therapies that go beyond conventional medication management, reflecting a rising interest among investors and healthcare providers in new psychiatric modalities.

NRx Pharmaceuticals is concurrently advancing a drug development pipeline focused on central nervous system (“CNS”) disorders. Its lead asset, NRX-101, has received Breakthrough Therapy Designation from the FDA for treatment-resistant bipolar depression with acute suicidality. Another program, NRX-100, a preservative-free IV formulation of ketamine, has Fast Track status and is aimed at acute suicidality treatment.

For more information, visit the company’s website at www.NRxPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP

• Nightfood Holdings new executives have strong track records in a variety of spaces
• NGTF’s new leadership team is poised to leverage their combined expertise to facilitate the company’s growth and innovation

The foundation of any successful company often rests on the quality and vision of its leadership. Experienced executives can be the deciding factor between stagnation and rapid growth, particularly in dynamic sectors such as consumer goods and hospitality. That’s why Nightfood Holdings (OTCQB: NGTF) made waves recently with its announcement of new senior leadership appointments aimed at accelerating innovation and expansion across its growing portfolio of hospitality-focused services.

According to a McKinsey & Company study, companies in the top quartile for executive team effectiveness were 1.9 times more likely to post above-average profitability than their peers (https://ibn.fm/Bkk51). These types of numbers underscore the tangible impact that proven, visionary leaders can have in steering a company through market complexities, evolving consumer expectations, and scaling operations.

With this context in mind, Nightfood Holdings’ recent announcement is especially compelling. The company has appointed Jimmy Chan as Chief Executive Officer and Ried Floco as president and director (https://ibn.fm/GgEOw). These two executives have strong track records in a variety of spaces, including the hospitality sector, where automation and artificial intelligence are reshaping service. These appointments are part of Nightfood’s broader initiative to integrate robotics into the hospitality industry, aiming to enhance efficiency and customer experience.

“These leadership transitions mark a pivotal moment in Nightfood’s evolution, aligning the company with two seasoned executives whose combined experience in scaling businesses, leveraging automation and operating in public market environments will drive long-term shareholder value and disciplined growth,” the company noted in the announcement. 

Chan brings more than 20 years of entrepreneurial and capital markets expertise across industries including real estate, international trade, healthcare and hospitality supply. “As the founder of CarryOutSupplies.com, he scaled one of the largest custom-printed foodservice packaging providers in North America, serving thousands of hotels and restaurants,” the company noted. 

Chan is a recognized leader in operational optimization, vertical integration and supply distribution. His experience in taking companies public, executing M&A transactions and restructuring businesses for long-term value creation will support Nightfood’s corporate development, capital markets strategy, and execution as a high-growth public enterprise.

With more than three decades of executive leadership across the hospitality sector, Floco has overseen the performance of some 200 hotel properties and $3 billion in asset valuations. He has led operations across top-tier brands, including Marriott, Hilton, Intercontinental and Starwood Hotels. 

“Floco will drive Nightfood’s Robotics-as-a-Service (‘RaaS’) platform deployment across hospitality verticals while simultaneously leading the company’s hotel asset acquisition strategy,” the company stated. “His deep operational insight will ensure that the integration of AI-powered automation with real estate ownership delivers scalable and efficient performance in Nightfood’s expanding portfolio.

Nightfood’s new leadership team is poised to leverage their combined expertise to facilitate the company’s growth and innovation. By focusing on the integration of AI and robotics into hospitality services, Nightfood Holdings is dedicated to solving current industry challenges. The company’s strategic vision includes expanding its reach and establishing NGTF as a leader in hospitality automation.

As Nightfood Holdings embarks on its next growth phase, the addition of industry-proven leaders reflects the company’s ambitions to scale, diversify, and lead in both the consumer wellness and hospitality innovation spaces. With experienced minds guiding its strategic direction, Nightfood is poised to convert vision into measurable value for stakeholders, customers, and partners alike.

For more information, visit the company’s website at NightfoodHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF

• Buprenorphine is a medication approved by the U.S. Food and Drug Administration (“FDA”) to treat opioid use disorder and chronic and severe pain
• Nutriband is developing a novel transdermal delivery system for buprenorphine, projected to reach peak annual sales of $70M – $130M
• The company’s AVERSA pipeline currently includes two main candidates: AVERSA(TM) Fentanyl and AVERSA(TM) Buprenorphine

As the opioid epidemic continues to pose one of the most critical public health crises in the United States and around the world, the need for innovative, safer treatments has never been more urgent. One company, Nutriband (NASDAQ: NTRB), is aiming to transform how opioid-based therapies are administered and protected against misuse, using its proprietary Aversa technology to set a new standard for transdermal pain and addiction treatments.

Buprenorphine, the next candidate for Aversa, is a medication approved by the U.S. Food and Drug Administration (“FDA”) to treat opioid use disorder (“OUD”) (https://ibn.fm/eQizg). Like NTRB’s Fentanyl patch, it offers an effective and safer alternative to full opioid agonists and has become a cornerstone in medication-assisted treatment (“MAT”) for OUD.

Clinical research supports buprenorphine’s advantages over other opioid treatments. A 2018 study published by the National Institute of Health found that patients with OUD treated with buprenorphine following a nonfatal opioid overdose are associated with significant reductions in opioid related mortality (https://ibn.fm/PYwdo).

NTRB is building on this momentum with their novel transdermal delivery system for buprenorphine, using its patented Aversa abuse-deterrent technology. Rather than relying on traditional oral films or sublingual tablets, Nutriband’s model involves embedding aversive agents into the patch itself, which deters misuse by producing unpleasant effects if the product is tampered with or consumed orally or intravenously. This innovation is especially important given the high rates of misuse associated with even prescribed opioid therapies.

The company’s Aversa pipeline currently includes two main opioid candidates: AVERSA(TM) Fentanyl and AVERSA(TM) Buprenorphine. AVERSA(TM) Fentanyl, Nutriband’s most advanced product, integrates the deterrent system with an FDA-approved fentanyl patch developed by Kindeva Drug Delivery. According to Nutriband, this would be the world’s first abuse-deterrent fentanyl patch, potentially reducing the risk of diversion, misuse and accidental exposure in a category known for both its efficacy and danger.

AVERSA(TM) Buprenorphine, meanwhile, is being positioned as the next step in the company’s growth. In a market update and based off a Health Advances independent report, Nutriband projected potential peak annual sales of $70 million to $130 million for AVERSA(TM) Buprenorphine in the United States alone upon regulatory approval (https://ibn.fm/foAon). The company is also evaluating international commercialization opportunities, supported by its expanding global patent portfolio.

Nutriband’s broader mission is to develop technologies that reduce the potential for abuse and misuse in pain and addiction treatment. The Aversa platform is designed to be applied to a range of transdermal therapies beyond fentanyl and buprenorphine, potentially addressing multiple categories of prescription misuse. The company believes that its approach could help bridge the gap between effective treatment and public health responsibility in the ongoing fight against opioid-related harm.

As regulators, physicians and patients alike seek new tools to battle the opioid epidemic, Nutriband’s efforts could prove pivotal. If successfully commercialized, Aversa-based products may offer a much-needed blend of efficacy, safety and innovation in a space that has long been fraught with challenges. 

For more information, visit the company’s website at www.Nutriband.com.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

• Fiscal 2025 marked record revenues of nearly $299 million, with silver production of 6.9 million ounces and 11% year-over-year growth in silver equivalent output.
• The company maintains industry-leading margins with an all-in sustaining cost of $12.12 per ounce of silver over the last 12 months, reinforcing its position as a low-cost producer.
• The company maintains a strong balance sheet with over $369 million in cash and a strategic equity portfolio, ensuring financial flexibility for future growth.
• The company launched construction of its fully funded El Domo copper-gold mine in 2025, with production expected by the end of 2026.
• Silvercorp has published an updated mineral resource estimate for the Condor Project and expects to issue a revised PEA by year-end 2025.
• Silvercorp is committed to strong environmental and social governance practices, holding an MSCI ESG rating of “A” and prioritizing local employment and procurement.

Silvercorp Metals (NYSE American: SVM) (TSX: SVM) is a Canadian mining company producing silver, gold, lead, and zinc, with a long history of profitability and growth. The company focuses on creating shareholder value by generating free cash flow from long-life mines, expanding through organic growth opportunities in China and Ecuador, and pursuing strategic mergers and acquisitions. Silvercorp has built a reputation as a low-cost producer with a commitment to responsible mining practices.

With over 18 years of operating experience, Silvercorp has developed a diversified portfolio of mining assets and investments in China, Ecuador, and Bolivia. The company leverages its expertise in exploration and operational efficiency to enhance the value of its projects while maintaining a strong balance sheet. Silvercorp’s disciplined approach to mine expansion and resource development ensures long-term sustainable growth.

The company’s mission is to build and operate profitable mines that generate sustainable economic, social, and environmental benefits for stakeholders. Silvercorp is committed to responsible mining, with a focus on environmental stewardship and community engagement.

The company is headquartered in Vancouver, Canada.

Portfolio

Silvercorp operates a diverse portfolio of producing mines, construction-stage projects, and exploration assets across multiple jurisdictions. The company focuses on optimizing production from existing operations while strategically advancing new projects to drive future growth.

• Ying Mining District (China) – The company’s flagship operation consists of several underground mines producing silver, gold, lead and zinc in concentrates. In fiscal 2025, Ying produced 6.9 million ounces of silver and 7,495 ounces of gold, along with lead and zinc by-products. Fiscal 2026 guidance calls for continued production growth as ongoing mine optimization efforts continue to bear fruit.
• GC Mine (China) – A silver-lead-zinc mine with a history of consistent production and ongoing resource expansion through drilling. While production dipped slightly in fiscal 2025, output is expected to increase in fiscal 2026.
• El Domo (Ecuador) – A fully-permitted, copper-gold project under construction. In April 2025, Silvercorp announced a detailed and fully funded $240.5 million construction plan. Major contracts have been awarded and construction activities are underway, with commissioning expected by December 2026.
• Condor Project (Ecuador) – A gold exploration asset with significant resources. In May 2025, Silvercorp published an updated mineral resource estimate focusing on high-grade underground zones. A revised PEA is expected by the end of 2025, alongside continued permitting and community engagement efforts.
• Kuanping Project (China) – A permitted gold-lead-zinc satellite project north of Ying. Mine construction is underway and Kuanping will be an underground mine with ore to be milled at the Ying complex.
• BYP Mine (China) – A gold-lead-zinc project that operated previously and is now undergoing permitting as a gold mine.
• Bolivian Assets – Silvercorp holds a 28% stake in New Pacific Metals (TSX: NUAG, NYSE American: NEWP), providing indirect exposure to two world class silver projects: Silver Sand and Carangas.

Through its diversified portfolio, Silvercorp delivers exposure to operations generating growing cash-flow, as well as high-potential growth projects that will create long-term value for shareholders.

Market Opportunity

The global demand for silver, gold, and base metals remains strong, driven by industrial applications, investment demand, and renewable energy initiatives. Silvercorp is well positioned to capitalize on rising silver demand, particularly in China, where 80% of the world’s solar panels are manufactured—an industry heavily reliant on silver.

Ecuador’s mining sector is experiencing rapid growth, with government support for foreign investment and infrastructure improvements. Mining exports in the country surged from $275 million in 2018 to $3.3 billion in 2023, highlighting the sector’s increasing economic importance. Silvercorp’s El Domo and Condor projects are poised to become key contributors to Ecuador’s mining expansion.

Industry forecasts indicate continued growth in silver and base metal prices, benefiting producers with strong operational performance and cost controls. Silvercorp’s diversified asset base and low-cost production profile provide resilience against market fluctuations, positioning the company for long-term value creation.

Leadership Team

Rui Feng, Ph.D., Chairman and CEO, founded Silvercorp and has over 30 years of experience in mineral exploration and mining. He has been instrumental in leading the company’s strategic vision, transforming it into a profitable, low-cost silver producer with a diversified asset base. Under his leadership, Silvercorp has expanded its global footprint, acquiring and developing high-value mining projects across China, Ecuador, and Bolivia. Dr. Feng’s expertise in geology and resource development has contributed to major mineral discoveries, and his disciplined approach to capital allocation has positioned the company for long-term growth.

Derek Liu, MBA, CGA, CPA, Chief Financial Officer, brings over two decades of financial leadership experience in the mining sector, overseeing capital allocation, financial strategy, and risk management. He has played a crucial role in maintaining Silvercorp’s strong balance sheet and financial discipline, ensuring the company remains well-capitalized for organic growth and strategic acquisitions. His expertise in financial planning, compliance, and investor relations has supported Silvercorp’s continued profitability and operational efficiency in a competitive global mining landscape.

Lon Shaver, CFA, President, has extensive experience in corporate finance, equity research, and capital markets, providing strategic guidance on business development and investor relations. Before joining Silvercorp, he held senior roles in investment banking and asset management, where he advised mining companies on financing, mergers, and acquisitions. His deep understanding of capital markets and industry dynamics helps drive Silvercorp’s corporate growth initiatives, enhance shareholder value, and strengthen relationships with institutional investors and stakeholders.

For more information, visit the company’s website at https://silvercorpmetals.com.

NOTE TO INVESTORS: The latest news and updates relating to SVM are available in the company’s newsroom at https://ibn.fm/SVM

• NTRB listed on the Nasdaq in 2021, is trading above its IPO price, and hit an all-time high of $11.78 in January of this year
• Nutriband’s AVERSA abuse-deterrent patch technology is FDA-bound and could command a market potential as high as $800 million annually

Serguei Melnik, Founder and President of Nutriband (NASDAQ: NTRB), recently joined The Smart Money Circle Show, where he pulled back the curtain on his no-nonsense approach to biotech entrepreneurship. His grounded tone and unwavering focus on long-term value stand in stark contrast to the conventional biotech playbook.

As is typical, the topic of the article focused on Nutriband’s history, technology, and vision. To that point, Nutriband’s core innovation is AVERSA, an abuse-deterrent technology designed to prevent the oral misuse of transdermal patches, particularly fentanyl, which can be 100 times more potent than heroin. The AVERSA system embeds ultra-bitter and ultra-spicy components that, in Melnik’s words, make it “almost impossible for abuse or misuse.” In short, risk of abuse is greatly reduced considering in order to ingest a drug like fentanyl, it will be accompanied by a taste akin to Bitrex meeting Pepper X, a real breakthrough in drug safety.

Adult misuse is one thing, but there is also a very real threat of potential death to children who unknowingly are exposed to residual amounts of fentanyl on patches.

The technology is now patented in more than 45 countries, and Nutriband is partnered with Kindeva Drug Delivery to commercialize new products. The company sees the next major milestone as an FDA submission seeking to bring the product to market.

According to Health Advances, the initial market opportunity for abuse-deterrent fentanyl patches could be between $80–$200 million in the first year of launch. If the FDA mandates such technologies, Melnik estimates the opportunity could swell to $800 million annually. Beyond fentanyl, AVERSA is a platform technology that could be adapted for other pain medications, creating multiple commercial pathways.

Doing It Differently from the Start

Unlike most biotech companies that go public with bloated capital raises, Nutriband went public via a Form 10 filing, handling even the legal work in-house with minimal funds. When bankers offered them tens of millions of dollars early on, Melnik walked away, believing it would ultimately destroy shareholder value. He cites peers who accepted similar terms and are now trading at fractions of their former selves – if they’re still trading at all. Meanwhile, Nutriband continues to trade above its IPO price and even hit an all-time high of $11.78 in January.

Outsmarting the Market and Protecting Shareholders

Melnik spoke candidly about how he witnessed the tactics of Wall Street firsthand. He shared a striking story of how market manipulators seemingly used company news against them. After observing suspicious trading patterns, Nutriband began keeping developments under wraps. In one example, when a patent was quietly announced in late 2021, shares surged from $3 to $10.44 on nearly 150 million shares of volume, the most active stock on Nasdaq that day. The lesson: silence can sometimes protect momentum.

Rather than fight Wall Street games, Melnik and his team took a different route to preserve capital. In 2022, the entire executive team took a 50% pay cut, saving $600,000 and extending their runway by over two years. That financial discipline attracted long-term allies, including a billionaire new investor, who has been very supportive of the company as it nears FDA submission for its flagship product.

Beyond Biotech: Diversified Revenue Streams and Transdermal Expertise

Unlike most early-stage biotech companies, Nutriband generates revenue today. The company operates a manufacturing facility in North Carolina that produces the Active Intelligence tape used by Reebok, among others. They also recently launched a mosquito-repelling patch, now approved for sale in Costa Rica. Melnik and his team personally tested the product by trekking through the Talamanca Mountain range without a single mosquito bite in four days.

Transdermal expertise is Nutriband’s hallmark, and Melnik is as committed as ever. “We only try to control what we can control,” he said. “If Wall Street funds don’t understand that we’re not coming back to them, I don’t know what else will make them.”

Leadership That Puts People First

Melnik isn’t just a President; he’s a founder with skin in the game, having tested products himself and taken financial hits to keep the company alive. Yet when asked in the podcast to share advice with his younger self, he didn’t talk about business plans or capital raises. He spoke about family and time.

His grounded mindset, passion for innovation, and unwillingness to compromise on shareholder value position Nutriband as a rare biotech story, one led by integrity, resilience, and vision that is nearing some critical milestones that could serve as significant catalysts to corporate value.

For more information, visit the company’s website at www.Nutriband.com.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

MoneyShow, a financial conference and content company that connects experts directly with entrepreneurs and investors, is proud to announce the Mid-Year Portfolio Review Virtual Expo. This online event, scheduled for June 17-18, is an excellent way for attendees to review where markets currently stand and where they are going. It also represents an opportunity for investors and traders to discover timely and practical recommendations that can be implemented right away.

This virtual experience will feature a variety of informative and authoritative speakers, including John Rutledge, Nancy Davis, Avi Gilburt, Jeffrey Hirsch, and Amy Smith. They will discuss mainstream and alternative investments in depth, including stocks, cryptocurrencies, private credit/private equity, precious metals, and real estate. The highly interactive format will also include plenty of time for networking and Q&A.

MoneyShow has built a legacy spanning 44 years, educating individuals passionate about investing and trading at both online and live events. Its strategic and intentional approach has yielded some of the most successful virtual and in-person conferences throughout the years. Both have been lauded for how informative they are and how great a networking opportunity they have proven to be.

The Mid-Year Portfolio Review Expo will be no different. It will be the go-to expo for attendees to learn about the different wealth-building alternatives and how they can boost portfolio performance. It will be a chance for those who sign up to learn about the best plays for the second half of 2025, giving them tremendous leverage over other investors.

Interested persons can get a first-hand look inside the MoneyShow virtual platform. There, they can view videos from previous events and read through live presentations covering everything from market analysis to portfolio recommendations to cutting-edge trading strategies and tools. They can also access a growing collection of educational resources, including a digital briefcase to store what they collect.

Registration for the expo is free and is still open.

To learn more, please visit https://ibn.fm/YN76c